A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B Infection
Status:
Completed
Trial end date:
2019-07-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if ABI-H0731 given in combination with a standard
of care (SOC) hepatitis B virus (HBV) nucleos(t)ide reverse transcriptase inhibitor (NUC)
medication is safe and effective in participants with chronic hepatitis B virus infection
(cHBV).